Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC303 in Immune Glomerular Diseases
NCT07000292Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of MBS303 in lupus nephritis (LN), ANCA-associated glomerulonephritis (ANCA-GN), sponsored by Shanghai Changzheng Hospital. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
MBS303
03
Conditions
lupus nephritis (LN)ANCA-associated glomerulonephritis (ANCA-GN)
Beyond the preview
Go deeper on NCT07000292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000292.